Current and future burden of breast cancer: Global statistics for 2020 and 2040
- PMID: 36084384
- PMCID: PMC9465273
- DOI: 10.1016/j.breast.2022.08.010
Current and future burden of breast cancer: Global statistics for 2020 and 2040
Abstract
Background: Breast cancer is the most commonly diagnosed cancer worldwide, and its burden has been rising over the past decades. In this article, we examine and describe the global burden of breast cancer in 2020 and predictions for the year 2040.
Methods: Estimates of new female breast cancer cases and deaths in 2020 were abstracted from the GLOBOCAN database. Age-standardized incidence and mortality rates were calculated per 100,000 females by country, world region, and level of human development. Predicted cases and deaths were computed based on global demographic projections for the year 2040.
Results: Over 2.3 million new cases and 685,000 deaths from breast cancer occurred in 2020. Large geographic variation across countries and world regions exists, with incidence rates ranging from <40 per 100,000 females in some Asian and African countries, to over 80 per 100,000 in Australia/New Zealand, Northern America, and parts of Europe. Smaller geographical variation was observed for mortality; however, transitioning countries continue to carry a disproportionate share of breast cancer deaths relative to transitioned countries. By 2040, the burden from breast cancer is predicted to increase to over 3 million new cases and 1 million deaths every year because of population growth and ageing alone.
Conclusion: Breast cancer is the most common cancer worldwide and continues to have a large impact on the global number of cancer deaths. Global efforts are needed to counteract its growing burden, especially in transitioning countries where incidence is rising rapidly, and mortality rates remain high.
Keywords: Breast cancer; Global; Incidence; Mortality; Prediction.
Copyright © 2022 World Health Organization. Published by Elsevier Ltd.. All rights reserved.
Figures




Similar articles
-
Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050.Breast. 2025 Feb;79:103835. doi: 10.1016/j.breast.2024.103835. Epub 2024 Nov 12. Breast. 2025. PMID: 39549557 Free PMC article.
-
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN.Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736. Epub 2022 Sep 8. Gut. 2023. PMID: 36604116
-
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.JAMA Dermatol. 2022 May 1;158(5):495-503. doi: 10.1001/jamadermatol.2022.0160. JAMA Dermatol. 2022. PMID: 35353115 Free PMC article.
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4. Gastroenterology. 2022. PMID: 35671803 Review.
Cited by
-
Combining metabolomics and machine learning to discover biomarkers for early-stage breast cancer diagnosis.PLoS One. 2024 Oct 21;19(10):e0311810. doi: 10.1371/journal.pone.0311810. eCollection 2024. PLoS One. 2024. PMID: 39432469 Free PMC article.
-
New Pyrazole/Pyrimidine-Based Scaffolds as Inhibitors of Heat Shock Protein 90 Endowed with Apoptotic Anti-Breast Cancer Activity.Pharmaceuticals (Basel). 2024 Sep 27;17(10):1284. doi: 10.3390/ph17101284. Pharmaceuticals (Basel). 2024. PMID: 39458925 Free PMC article.
-
STAT3: Key targets of growth-promoting receptor positive breast cancer.Cancer Cell Int. 2024 Oct 28;24(1):356. doi: 10.1186/s12935-024-03541-9. Cancer Cell Int. 2024. PMID: 39468521 Free PMC article. Review.
-
HER2-low non-metastatic breast cancer in Qatar-a nationwide retrospective cohort study to evaluate the response to neoadjuvant chemotherapy: a real-world analysis.Front Oncol. 2024 Oct 16;14:1398100. doi: 10.3389/fonc.2024.1398100. eCollection 2024. Front Oncol. 2024. PMID: 39479022 Free PMC article.
-
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel.Cancers (Basel). 2024 Jan 11;16(2):306. doi: 10.3390/cancers16020306. Cancers (Basel). 2024. PMID: 38254795 Free PMC article. Review.
References
-
- Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–249. - PubMed
-
- Heer E., Harper A., Escandor N., Sung H., McCormack V., Fidler-Benaoudia M.M. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Global Health. 2020;8(8):e1027–e1037. - PubMed
-
- Anderson B.O., Ilbawi A.M., Fidarova E., Weiderpass E., Stevens L., Abdel-Wahab M., Mikkelsen B. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021;22(5):578–581. - PubMed
-
- Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778–789. - PubMed
-
- Global Cancer Observatory: Cancer Today [https://gco.iarc.fr/today/home].
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous